LILLE, France and CAMBRIDGE, Mass., Oct. 25 /PRNewswire/ -- GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announced that it has been selected by Windhover as one of the "Top Biopharma Projects To Watch" in 2011 in the cardiovascular/metabolic category. This announcement is part of the conference event organized by Elsevier Business Intelligence and Windhover Conferences taking place in Boston from November 2-4, 2010, where GENFIT will be presenting its latest scientific achievements.
"This year's list is handpicked in the six hottest therapeutic areas," said David Cassak, vice president, content, for Elsevier Business Intelligence's publications. "Many of our past winners have gone on to do big deals, and we expect the same from this year's companies."
The Windhover conference annually elects 10 biopharmaceutical companies with high-value assets for partnership in six specific therapeutic areas: cardiovascular/metabolic, oncology, neuroscience, infectious diseases, inflammatory/autoimmune and a category including ophthalmology, orphan diseases, and women's health.
Dr. Dean W. Hum, chief scientific officer of GENFIT, added, "Being a well recognized company in the U.S. in our specific therapeutic area is a great honor for us. We will present our most advanced drug candidate in the field of diabetes, GFT505, and our specific and innovative approach to the prevention and treatment of cardiometabolic diseases. This will be illustrated by the presentation of other internal research programs, in particular those dedicated to the discovery of early biomarkers and those dealing with the connection between circadian cycle dysregulation and metabolic diseases."
Windhover Information Inc, an Elsevier company, has provided analysis of the healthcare industry to decision-makers at all levels since the founding of its flagship publication, IN VIVO: The Business & Medicine Report, in 1983. Windhover provides its information and analysis in many formats, including print, electronic databases, international conferences and webinars. For more on the company's products and services, please see www.windhover.com.
GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases…). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies (SANOFI-AVENTIS, SERVIER, ...), to address these major public health concerns and their unmet medical needs.
GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase II.
With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 100 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com
Jean-Francois Mouney – CEO & Chairman of the Management Board
+33 (0)3 2016 4000
Martina Schwarzkopf, Ph.D.
+1 212 845-4292 / +1 347 591 8785 - firstname.lastname@example.org
Milestones – Press Relations
+33 (0)1 75 44 87 40 / +33 (0)6 87 88 47 26 – email@example.com